Anthropometry (2)
- chght1 - Subject height (phv00492342.v3.p1)
- cwght1 - Subject weight (phv00492343.v3.p1)
Biomarkers (5)
- eosi_av - Percent eosinophils in blood from hematology analysis (phv00492344.v3.p1)
- IL5_co - In vitro PMA+ionomycin stimulated PBMCs IL5 production (phv00492351.v3.p1)
- lymp_av - Percent lymphocytes in blood from hematology analysis (phv00492345.v3.p1)
- mono_av - Percent monocytes in blood from hematology analysis (phv00492346.v3.p1)
- neut_av - Percent neutrophils in blood from hematology analysis (phv00492347.v3.p1)
Demographics (4)
- cage1 - Subject age (phv00492341.v3.p1)
- csex1_0 - Subject sex (phv00492358.v2.p1)
- SEX - Subject self-reported sex (phv00492336.v2.p1)
- Wave - Wave of longitudinal data collection (phv00528205.v2.p1)
Reproductive Health (3)
- cbpd - Pubertal development score - male (phv00528214.v2.p1)
- cgpd - Pubertal development score - female (phv00528212.v2.p1)
- cgpd5 - Menarche status (phv00528213.v2.p1)
Respiratory (10)
- aBPFAM - Peak flow AM (phv00528208.v2.p1)
- aBPFPM - Peak flow PM (phv00528209.v2.p1)
- cdatot - Self-reported daily asthma symptoms (phv00528211.v2.p1)
- csasgm - Self-reported nightly asthma symptoms (phv00492354.v3.p1)
- csinhl - Self-reported nightly inhaler use (phv00492355.v3.p1)
- ctasev - Self-reported asthma symptom severity (phv00492356.v3.p1)
- ctasfq - Self-reported asthma symptom frequency (phv00528210.v2.p1)
- FEVPP - FEV1 percent predicted (phv00492353.v3.p1)
- FFPP - FEV1/FVC percent predicted (phv00528207.v2.p1)
- FVCPP - FVC percent predicted (phv00528206.v2.p1)
Sleep (1)
- cssdh - Self-reported sleep duration (phv00492365.v2.p1)
Other (37)
- ANALYTE_TYPE - Analyte Type (phv00492369.v2.p1)
- ANALYTE_TYPE - Analyte Type (phv00529310.v1.p1)
- ANALYTE_TYPE - Analyte Type (phv00555620.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00492368.v2.p1)
- BODY_SITE - Body site where sample was collected (phv00529309.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00555619.v1.p1)
- cddstf - Self-reported self-disclosure (phv00492349.v3.p1)
- ceth1_0 - Subject self-reported ethnicity (phv00492359.v2.p1)
- CONSENT - Consent group as determined by DAC (phv00492335.v2.p1)
- cpeqcm - Self-reported parent-child conflict with mother figure (phv00492350.v3.p1)
- ECNA_0 - Objectively-assessed negative affect (phv00492364.v2.p1)
- EPMres_0 - Objectively-assessed parental responsiveness of mother (phv00492362.v2.p1)
- EYell_0 - Objectively-assessed family conflict (phv00492363.v2.p1)
- fraction_mapped - Fraction of reads mapping to exons (phv00492373.v2.p1)
- is_tumor - Is sample derived from tumor tissue? (phv00493279.v2.p1)
- IS_TUMOR - Tumor status (phv00529311.v1.p1)
- IS_TUMOR - Tumor status (phv00555621.v1.p1)
- Lab - Laboratory where RNA was isolated (phv00492372.v2.p1)
- log2FC.IL13 - In vitro IL13 glucocorticoid resistance (phv00492352.v3.p1)
- percent_clean - Fraction of reads remaining after QC (phv00492374.v2.p1)
- PGOODFAIR_0 - Proportion of houses rated fair or better in neighborhood (phv00492360.v2.p1)
- Plate - Library preparation batch (phv00492370.v2.p1)
- POOLED_SUBJECT_ID - Pooled subject ID (phv00529307.v1.p1)
- psesl - Parent-reported subjective socioeconomic status (phv00492348.v3.p1)
- PUNOCC_0 - Proportion of houses unoccupied in neighborhood (phv00492361.v2.p1)
- Resztak2021 - Sample used in Resztak, 2021 (DOI:10.7554/eLife.63852) (phv00528215.v1.p1)
- Resztak2023 - Sample used in Resztak, 2023 (DOI: 10.1038/s41467-022-35742-z) (phv00528216.v1.p1)
- RIN - RNA integrity number (phv00492371.v2.p1)
- SAMPLE_ID - De-identified Sample ID (phv00492366.v2.p1)
- SAMPLE_ID - De-identified Sample ID (phv00529308.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00555618.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00492338.v4.p1)
- SUBJECT_ID - Subject ID (phv00492339.v3.p1)
- SUBJECT_ID - Subject ID (phv00492357.v2.p1)
- SUBJECT_ID - Subject ID (phv00492334.v2.p1)
- SUBJECT_ID - De-identified Subject ID (phv00492337.v4.p1)
- Wave - Sample collection wave (phv00492367.v2.p1)